Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02782104




Registration number
NCT02782104
Ethics application status
Date submitted
29/04/2016
Date registered
25/05/2016
Date last updated
20/02/2024

Titles & IDs
Public title
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Scientific title
An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Secondary ID [1] 0 0
54135419TRD3008
Secondary ID [2] 0 0
CR108149
Universal Trial Number (UTN)
Trial acronym
SUSTAIN-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Depressive Disorder, Treatment-Resistant 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Esketamine Nasal Spray

Experimental: Esketamine Nasal Spray - Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.


Treatment: Drugs: Esketamine Nasal Spray
Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) Score
Timepoint [1] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [2] 0 0
Change From Study Baseline in Computerized Cognitive Battery Domain Score: Identification Test (IDN) Score
Timepoint [2] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [3] 0 0
Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Card Learning Test (OCL) Score
Timepoint [3] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [4] 0 0
Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Back Test (ONB) Score
Timepoint [4] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [5] 0 0
Change From Study Baseline in Computerized Cognitive Battery Domain Score: Groton Maze Learning Test (GMLT) Score
Timepoint [5] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [6] 0 0
Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score
Timepoint [6] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [7] 0 0
Percentage of Participants Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Timepoint [7] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [8] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Timepoint [8] 0 0
IND Phase: up to 4 weeks; OP/MA Phase: up to 78 months
Primary outcome [9] 0 0
Change From Baseline in Heart Rate
Timepoint [9] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [10] 0 0
Change From Baseline in Systolic and Diastolic Blood Pressure
Timepoint [10] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [11] 0 0
Change From Baseline in Respiratory Rate
Timepoint [11] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Primary outcome [12] 0 0
Change From Baseline in Blood Oxygen Saturation
Timepoint [12] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Secondary outcome [1] 0 0
Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score
Timepoint [1] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Secondary outcome [2] 0 0
Change From Baseline in Participant-Reported Depressive Symptoms Using the Patient Health Questionnaire - 9 (PHQ-9) Total Score
Timepoint [2] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Secondary outcome [3] 0 0
Change From Baseline in Clinical Global Impression-severity (CGI-S) Score
Timepoint [3] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Secondary outcome [4] 0 0
Change From Baseline in Sheehan Disability Scale (SDS) Total Score
Timepoint [4] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Secondary outcome [5] 0 0
Change From Baseline in Participant-Reported Health-related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Valuation Index Score (VAS)
Timepoint [5] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Secondary outcome [6] 0 0
Change From Baseline as Assessed by EQ 5D-5L: Sum Score
Timepoint [6] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months
Secondary outcome [7] 0 0
Change From Baseline in Participant- Reported Health Related Quality of Life Using the Quality of Life in Depression Scale (QLDS)
Timepoint [7] 0 0
IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months

Eligibility
Key inclusion criteria
* Based on the prior study the participant is entering 54135419TRD3008 from: a) From ESKETINTRD3001 (NCT02417064) or ESKETINTRD3002 (NCT02418585) study: Participant has completed the induction phase and the 2-weeks follow up phase visit; or Participants completed the induction phase and was a responder and study ESKETINTRD3003 is terminated.; b) From ESKETINTRD3003 (NCT02493868) study: (1) Participant relapsed during the maintenance phase; or (2) Participant was in the induction phase of the ESKETINTRD3003 study when the study was terminated and, after completion of the induction phase, was determined to be a responder; or (3) Participant was in the optimization or maintenance phases at the time the study was terminated; or (4) or (5) Participants was in the induction phase and after completion of induction phase was determined to not meet response criteria (1) Participant completed ESKETINTRD3004 study (optimization/maintenance phase); or (2) Participant was in the induction phase of the ESKETINTRD3004 study when the study was terminated and, after completion of the induction phase, was determined to be a responder; or (3) Participant was in the optimization/maintenance phase at the time the study was terminated; (4) Participant was in the induction phase and did not meet criteria for response may be eligible for to be rolled over into 54135419TRD3008. d) From ESKETINTRD3005 (NCT02422186) study: Participant was in the induction phase of the ESKETINTRD3005 study at the time enrollment into the ESKETINTRD3004 study was closed and, after completion of the induction phase, was determined to be a responder or did not meet the criteria for response. e) From ESKETINTRD3006 study (US Study sites only) (1) Participant completed the induction phase and was a responder.
* Participant must be medically stable on the basis of physical examination, vital signs, pulse oximetry, and 12-lead Electrocardiogram (ECG) performed predose on the day of the first intranasal treatment session. If there are any abnormalities that are not specified in the inclusion and exclusion criteria, their clinical significance must be determined by the investigator and recorded in the participant's source documents and initialed by the investigator
* Participant must be medically stable according to the investigator's judgment and knowledge of the subject's medical stability in the parent study. This determination must be documented.
* A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [b-hCG]) predose on the day of the first intranasal treatment session
* During the study (that is, from the first intranasal treatment session) and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of intranasal study medication, a man who is sexually active with a woman of childbearing potential must be practicing a highly effective method of contraception with his female partner c) must agree not to donate sperm.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* The evaluation of the benefit versus risk of continued esketamine nasal spray treatment is not favorable for the participant in the opinion of the investigator
* Since the last study visit in the participant's prior study, participant has suicidal ideation with intent to act per the investigator's clinical judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS) [corresponding to a response of "Yes" on Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) in the suicidal ideation module of the C-SSRS] or suicidal behavior per the investigator's clinical judgment or based on the C-SSRS (corresponding to any score higher than 0 in the suicidal behavior module of the C-SSRS)
* Participant has positive test result(s) for drugs of abuse (including barbiturates, methadone, opiates, cocaine, phencyclidine, and amphetamine/methamphetamine) predose on the day of the first intranasal treatment session
* Participant has any anatomical or medical condition that, per the investigator's clinical judgment based on assessment, may impede delivery or absorption of intranasal study drug
* Participant has taken any prohibited therapies that would not permit administration of the first intranasal treatment session

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/06/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/12/2022
Sample size
Target
Accrual to date
Final
1148
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Caulfield
Recruitment hospital [2] 0 0
- Elizabeth Vale
Recruitment hospital [3] 0 0
- Frankston
Recruitment postcode(s) [1] 0 0
- Caulfield
Recruitment postcode(s) [2] 0 0
- Elizabeth Vale
Recruitment postcode(s) [3] 0 0
- Frankston
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Rhode Island
Country [22] 0 0
United States of America
State/province [22] 0 0
South Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Virginia
Country [25] 0 0
United States of America
State/province [25] 0 0
Wisconsin
Country [26] 0 0
Argentina
State/province [26] 0 0
Banfield
Country [27] 0 0
Argentina
State/province [27] 0 0
Ciudad Autonoma de Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Ciudad Autónoma De Buenos Aires
Country [29] 0 0
Argentina
State/province [29] 0 0
Cordoba
Country [30] 0 0
Argentina
State/province [30] 0 0
La Plata
Country [31] 0 0
Argentina
State/province [31] 0 0
Mendoza
Country [32] 0 0
Argentina
State/province [32] 0 0
Rosario
Country [33] 0 0
Austria
State/province [33] 0 0
Vienna
Country [34] 0 0
Belgium
State/province [34] 0 0
Aalst
Country [35] 0 0
Belgium
State/province [35] 0 0
Brugge
Country [36] 0 0
Belgium
State/province [36] 0 0
Brussel
Country [37] 0 0
Belgium
State/province [37] 0 0
Heusden-Zolder
Country [38] 0 0
Belgium
State/province [38] 0 0
Liège
Country [39] 0 0
Belgium
State/province [39] 0 0
Yvoir
Country [40] 0 0
Brazil
State/province [40] 0 0
Belo Horizonte
Country [41] 0 0
Brazil
State/province [41] 0 0
Curitiba
Country [42] 0 0
Brazil
State/province [42] 0 0
Fortaleza
Country [43] 0 0
Brazil
State/province [43] 0 0
Passo Fundo
Country [44] 0 0
Brazil
State/province [44] 0 0
Porto Alegre
Country [45] 0 0
Brazil
State/province [45] 0 0
Recife
Country [46] 0 0
Brazil
State/province [46] 0 0
Rio de Janeiro
Country [47] 0 0
Brazil
State/province [47] 0 0
Sao Bernardo do Campo
Country [48] 0 0
Brazil
State/province [48] 0 0
Sao Paulo
Country [49] 0 0
Brazil
State/province [49] 0 0
São Paulo
Country [50] 0 0
Bulgaria
State/province [50] 0 0
Bourgas
Country [51] 0 0
Bulgaria
State/province [51] 0 0
Kardzhali
Country [52] 0 0
Bulgaria
State/province [52] 0 0
Pazardzhik
Country [53] 0 0
Bulgaria
State/province [53] 0 0
Pleven
Country [54] 0 0
Bulgaria
State/province [54] 0 0
Plovdiv
Country [55] 0 0
Bulgaria
State/province [55] 0 0
Rousse
Country [56] 0 0
Bulgaria
State/province [56] 0 0
Sofia
Country [57] 0 0
Bulgaria
State/province [57] 0 0
Varna
Country [58] 0 0
Canada
State/province [58] 0 0
British Columbia
Country [59] 0 0
Canada
State/province [59] 0 0
Ontario
Country [60] 0 0
Czechia
State/province [60] 0 0
Brno
Country [61] 0 0
Czechia
State/province [61] 0 0
Plzen
Country [62] 0 0
Czechia
State/province [62] 0 0
Prague
Country [63] 0 0
Czechia
State/province [63] 0 0
Praha 10
Country [64] 0 0
Czechia
State/province [64] 0 0
Praha 2
Country [65] 0 0
Czechia
State/province [65] 0 0
Praha 6
Country [66] 0 0
Estonia
State/province [66] 0 0
Tallinn
Country [67] 0 0
Estonia
State/province [67] 0 0
Tartu
Country [68] 0 0
Finland
State/province [68] 0 0
Kuopio
Country [69] 0 0
France
State/province [69] 0 0
Clermont-Ferrand Cedex 1
Country [70] 0 0
France
State/province [70] 0 0
Douai
Country [71] 0 0
France
State/province [71] 0 0
Nantes
Country [72] 0 0
France
State/province [72] 0 0
Nîmes
Country [73] 0 0
France
State/province [73] 0 0
Paris
Country [74] 0 0
France
State/province [74] 0 0
Poitiers Cedex
Country [75] 0 0
France
State/province [75] 0 0
Toulon Cedex
Country [76] 0 0
Germany
State/province [76] 0 0
Berlin
Country [77] 0 0
Germany
State/province [77] 0 0
Bochum
Country [78] 0 0
Germany
State/province [78] 0 0
Mainz
Country [79] 0 0
Germany
State/province [79] 0 0
Mittweida
Country [80] 0 0
Germany
State/province [80] 0 0
Oranienburg
Country [81] 0 0
Germany
State/province [81] 0 0
Pfaffenhofen
Country [82] 0 0
Hungary
State/province [82] 0 0
Budapest
Country [83] 0 0
Hungary
State/province [83] 0 0
Debrecen
Country [84] 0 0
Hungary
State/province [84] 0 0
Gyor
Country [85] 0 0
Hungary
State/province [85] 0 0
Pecs
Country [86] 0 0
Hungary
State/province [86] 0 0
Sopron
Country [87] 0 0
Hungary
State/province [87] 0 0
Szekszárd
Country [88] 0 0
Hungary
State/province [88] 0 0
Vác
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Gwangju
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Seoul
Country [91] 0 0
Lithuania
State/province [91] 0 0
Kaunas
Country [92] 0 0
Malaysia
State/province [92] 0 0
Kuala Lumpur
Country [93] 0 0
Mexico
State/province [93] 0 0
Guadalajara
Country [94] 0 0
Mexico
State/province [94] 0 0
Leon
Country [95] 0 0
Mexico
State/province [95] 0 0
Mexico City
Country [96] 0 0
Mexico
State/province [96] 0 0
Mexico
Country [97] 0 0
Mexico
State/province [97] 0 0
Monterrey
Country [98] 0 0
Mexico
State/province [98] 0 0
San Luis Potosi
Country [99] 0 0
Poland
State/province [99] 0 0
Belchatow
Country [100] 0 0
Poland
State/province [100] 0 0
Bialystok
Country [101] 0 0
Poland
State/province [101] 0 0
Bydgoszcz
Country [102] 0 0
Poland
State/province [102] 0 0
Gdansk
Country [103] 0 0
Poland
State/province [103] 0 0
Leszno
Country [104] 0 0
Poland
State/province [104] 0 0
Lublin
Country [105] 0 0
Poland
State/province [105] 0 0
Warszawa
Country [106] 0 0
Slovakia
State/province [106] 0 0
Bratislava
Country [107] 0 0
Slovakia
State/province [107] 0 0
Liptovsky Mikulas
Country [108] 0 0
Slovakia
State/province [108] 0 0
Rimavska Sobota
Country [109] 0 0
Slovakia
State/province [109] 0 0
Roznava
Country [110] 0 0
Slovakia
State/province [110] 0 0
Svidnik
Country [111] 0 0
South Africa
State/province [111] 0 0
Cape Town
Country [112] 0 0
South Africa
State/province [112] 0 0
Pretoria
Country [113] 0 0
South Africa
State/province [113] 0 0
Welgemoed
Country [114] 0 0
Spain
State/province [114] 0 0
Alcorcón
Country [115] 0 0
Spain
State/province [115] 0 0
Barcelona
Country [116] 0 0
Spain
State/province [116] 0 0
Bilbao
Country [117] 0 0
Spain
State/province [117] 0 0
Madrid
Country [118] 0 0
Spain
State/province [118] 0 0
Oviedo
Country [119] 0 0
Spain
State/province [119] 0 0
Palma
Country [120] 0 0
Spain
State/province [120] 0 0
Pamplona
Country [121] 0 0
Spain
State/province [121] 0 0
Sabadell
Country [122] 0 0
Spain
State/province [122] 0 0
Salamanca
Country [123] 0 0
Spain
State/province [123] 0 0
Sant Boi de Llobregat
Country [124] 0 0
Spain
State/province [124] 0 0
Torrevieja
Country [125] 0 0
Spain
State/province [125] 0 0
Vitoria-Gasteiz
Country [126] 0 0
Spain
State/province [126] 0 0
Zamora
Country [127] 0 0
Sweden
State/province [127] 0 0
Halmstad
Country [128] 0 0
Sweden
State/province [128] 0 0
Lund
Country [129] 0 0
Sweden
State/province [129] 0 0
Skövde
Country [130] 0 0
Sweden
State/province [130] 0 0
Stockholm
Country [131] 0 0
Taiwan
State/province [131] 0 0
Kaohsiung
Country [132] 0 0
Taiwan
State/province [132] 0 0
New Taipei
Country [133] 0 0
Taiwan
State/province [133] 0 0
Taichung
Country [134] 0 0
Taiwan
State/province [134] 0 0
Taipei
Country [135] 0 0
Taiwan
State/province [135] 0 0
Taoyuan
Country [136] 0 0
Turkey
State/province [136] 0 0
Adana
Country [137] 0 0
Turkey
State/province [137] 0 0
Ankara
Country [138] 0 0
Turkey
State/province [138] 0 0
Bursa
Country [139] 0 0
Turkey
State/province [139] 0 0
Istanbul
Country [140] 0 0
Turkey
State/province [140] 0 0
Kucukcekmece/Istanbul
Country [141] 0 0
Turkey
State/province [141] 0 0
Oanakkale
Country [142] 0 0
Turkey
State/province [142] 0 0
Samsun
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Chesterfield
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Derby
Country [145] 0 0
United Kingdom
State/province [145] 0 0
London
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Northampton
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
Trial website
https://clinicaltrials.gov/study/NCT02782104
Trial related presentations / publications
Starr HL, Abell J, Larish A, Lewis S, DeMuro C, Gogate J, Jamieson C, Daly E, Zaki N, Kramer M. Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study. Psychiatry Res. 2020 Nov;293:113376. doi: 10.1016/j.psychres.2020.113376. Epub 2020 Aug 8.
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02782104